Evidence map›Paper›PMID 38493358›Full record

ArticleHuman molecular genetics2024

A loss of function mutation in CLDN25 causing Pelizaeus-Merzbacher-like leukodystrophy.

Yosuke Hashimoto, Claude Besmond, Nathalie Boddaert, Arnold Munnich, Matthew Campbell

Erratum issuedOpen access · hybridAbstract readCase Reports
In one paragraph

Article in Human molecular genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Yosuke HashimotoSmurfit Institute of Genetics, Trinity College Dublin, D02 VF25, Dublin, Ireland.
Claude BesmondINSERM UMR1163, Institut Imagine, Paris University, F-75015, Paris, France.
Nathalie BoddaertINSERM UMR1163, Institut Imagine, Paris University, F-75015, Paris, France.
Arnold MunnichINSERM UMR1163, Institut Imagine, Paris University, F-75015, Paris, France.
Matthew CampbellSmurfit Institute of Genetics, Trinity College Dublin, D02 VF25, Dublin, Ireland.
Inserm · FRInstitut des Maladies Génétiques Imagine · FRRoyal College of Surgeons in Ireland · IETrinity College Dublin · IE

Funding

Enterprise IrelandEuropean Regional DevelopmentEuropean Research Council 864522Irish Research CouncilScience Foundation Ireland (SFI) COVID-19 20/COV/0312SFI 21/RC/10294_P2SFI Eye-D-21/SPP/3732
6 · The paper itself

Abstract

Claudin-25 (CLDN-25), also known as Claudin containing domain 1, is an uncharacterized claudin family member. It has less conserved amino acid sequences when compared to other claudins. It also has a very broad tissue expression profile and there is currently a lack of functional information from murine knockout models. Here, we report a de novo missense heterozygous variant in CLDN25 (c. 745G>C, p. A249P) found in a patient diagnosed with Pelizaeus-Merzbacher-like leukodystrophy and presenting with symptoms such as delayed motor development, several episodes of tonic absent seizures and generalized dystonia. The variant protein does not localize to the cell-cell borders where it would normally be expected to be expressed. Amino acid position 249 is located 4 amino acids from the C-terminal end of the protein where most claudin family members have a conserved binding motif for the key scaffolding protein ZO-1. However, CLDN-25 does not contain this motif. Here, we show that the C-terminal end of CLDN-25 is required for its junctional localization in a ZO-1 independent manner. The A249P mutant protein as well as a deletion mutant lacking its last 5 C-terminal amino acids also failed to localize to the cell-cell border in vitro. Intriguingly, cellular knockout of CLDN25, in vitro, appeared to increase the integrity of the tight junction between 2 contacting cells, while driving highly unusual increased movement of solutes between cells. We propose that the barrier function of CLDN-25 is akin to a decoy claudin, whereby decreasing its expression in "leaky" epithelial cells and endothelial cells will drive dynamic changes in the adhesion and interaction capacity of cell-cell contact points. While it remains unclear how this de novo CLDN-25 mutant induces leukodystrophy, our findings strongly suggest that this mutation induces haploinsufficiency of CLDN-25. Elucidating the function of this uncharacterized claudin protein will lead to a better understanding of the role of claudin proteins in health and disease.

Indexed as

ClaudinsPelizaeus-Merzbacher DiseaseAmino Acid SequenceAnimalsFemaleHumansLoss of Function MutationMaleMutation, MissenseClaudinsCLDN25 protein, humanClaudin-25Leukodysdrophytight junctionZO-1

Identifiers

PMID38493358
PMCPMC11153337
OpenAlexW4392895405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.